Abstract
G protein-coupled receptor 124 (GPR124; also called tumor endothelial marker 5, TEM5) is highly expressed in tumor vasculature. While recent studies have revealed a role in vasculogenesis, evidence for GPR124 function in tumor angiogenesis is lacking. Here, we demonstrate that GPR124 is required for VEGFinduced tumor angiogenesis. GPR124 silencing in human endothelial cells inhibited mouse xenograft tumor angiogenic vessel formation and tumor growth. GPR124 regulated VEGF-induced tumor angiogenic processes in vitro including cell-cell interaction, permeability, migration, invasion, and tube formation. Therefore, GPR124 plays a key role in VEGF-induced tumor angiogenesis.
Keywords: Angiogenesis, cancer, G protein coupled receptors (GPCR), tumor, vascular biology, vascular endothelial growth factor (VEGF).
Current Molecular Medicine
Title:G-Protein Coupled Receptor 124 (GPR124) in Endothelial Cells Regulates Vascular Endothelial Growth Factor (VEGF)-Induced Tumor Angiogenesis
Volume: 14 Issue: 4
Author(s): Y. Wang, S.-G. Cho, X. Wu, S. Siwko and M. Liu
Affiliation:
Keywords: Angiogenesis, cancer, G protein coupled receptors (GPCR), tumor, vascular biology, vascular endothelial growth factor (VEGF).
Abstract: G protein-coupled receptor 124 (GPR124; also called tumor endothelial marker 5, TEM5) is highly expressed in tumor vasculature. While recent studies have revealed a role in vasculogenesis, evidence for GPR124 function in tumor angiogenesis is lacking. Here, we demonstrate that GPR124 is required for VEGFinduced tumor angiogenesis. GPR124 silencing in human endothelial cells inhibited mouse xenograft tumor angiogenic vessel formation and tumor growth. GPR124 regulated VEGF-induced tumor angiogenic processes in vitro including cell-cell interaction, permeability, migration, invasion, and tube formation. Therefore, GPR124 plays a key role in VEGF-induced tumor angiogenesis.
Export Options
About this article
Cite this article as:
Wang Y., Cho S.-G., Wu X., Siwko S. and Liu M., G-Protein Coupled Receptor 124 (GPR124) in Endothelial Cells Regulates Vascular Endothelial Growth Factor (VEGF)-Induced Tumor Angiogenesis, Current Molecular Medicine 2014; 14 (4) . https://dx.doi.org/10.2174/1566524014666140414205943
DOI https://dx.doi.org/10.2174/1566524014666140414205943 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics <i>In Vitro</i> Anticancer Activity of Virgin Coconut Oil and its Fractions in Liver and Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in the Modeling of Gastrointestinal Disorders
Current Stem Cell Research & Therapy Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Erratum
Current Proteomics miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery β-lactam Structured, 4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxyazetidin-2-one: Selectively Targets Cancerous B Lymphocyte Mitochondria
Anti-Cancer Agents in Medicinal Chemistry Novel Compounds from Marine Microorganisms that Inhibit Mammalian DNA Polymerase
Current Organic Chemistry Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Ulipristal Acetate (Esmya) in the Management of Heavy Menstrual Bleeding Associated with Fibroids: A Case Series
Current Women`s Health Reviews Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery Abnormal Signal Transduction via Over-expression of Pim-1 Regulated Senescence, Cell Cycle, Apoptosis and Metastatic Invasion: Novel Anticancer Targets and Their Potent Inhibitors from Marine Sources
Current Signal Transduction Therapy Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Current Advances in Retroviral Gene Therapy
Current Gene Therapy